Health
GC Biopharma Announces Symposium on Clinical and Patient Experience in Primary Immunodeficiency and Poster Presentations on IVIG Manufacturing and Viscosity at the 2025 IgNS Annual Meeting
GC Biopharma USA, Inc., a leader in plasma-derived products, announced today that it will host a sponsored symposium and present two scientific posters at the 2025 Immunoglobulin National Society (IgNS) Annual Meeting, taking place October 16-19 in Dallas, Texas. Together, these sessions will spotlight perspectives from patients, clinicians, and researchers and highlight advances in intravenous immunoglobulin (IVIG) treatment, including ALYGLO® (immune globulin intravenous, human-stwk, 10% liqui
About this update from Gc Biopharma Corp.
[{"type":"text","content":"Poster presentations will examine manufacturing process optimization for removal of impurities and the impact of temperature on IVIG viscosity","length":142,"tagName":"p","attribs":{}},{"type":"text","content":"TEANECK, N.J., Oct. 15, 2025 /PRNewswire/ -- GC Biopharma USA, Inc., a leader in plasma-derived products, announced today that it will host a sponsored symposium and present two scientific posters at the 2025 Immunoglobulin National Society (IgNS) Annual Meeting, taking place October 16-19 in Dallas, Texas. Together, these sessions will spotlight perspectives from patients, clinicians, and researchers and highlight advances in intravenous immunoglobulin (IVIG) treatment, including ALYGLO® (immune globulin intravenous, human-stwk, 10% liquid).","length":553,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/GC Biopharma USA Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/GC Biopharma USA Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":47,"url":"https://media.zenfs.com/en/prnewswire.com/43ba7eb5826798f9fa73aa32f8983d19"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hj5P5wfHr0LutqsDj_BN_g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTgzO2NmPXdlYnA-/https://media.zenfs.com/en/prnewswire.com/43ba7eb5826798f9fa73aa32f8983d19","width":400,"height":47}},"href":"https://mma.prnewswire.com/media/2292463/GC_LOGO__002_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""These sessions underscore GC Biopharma's commitment to advancing education in IVIG therapies by sharing important data and varied perspectives that support informed multidisciplinary patient-centered decision making," said Stacey Ness, PharmD, IgCP, CSP, MSCS, AAHIVP, Medical Affairs, GC Biopharma USA.","length":318,"tagName":"p"},{"type":"text","content":"The breakfast symposium, titled "From Patient Voices to Clinical Choices: Bridging Perspectives in Primary Immunodeficiency,"will be held on Saturday, October 18 from 7:30 am to 9:00 am CT. The program will feature perspectives from both clinicians and patients, with presentations by:","length":295,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Antoine Azar, MD, FAAAAI, Associate Professor of Medicine, Johns Hopkins Bayview Medical Center","length":95,"tagName":"p"}]},{"val":[{"type":"t...